Zevra Therapeutics Inc Revenue Growth Rates (ZVRA), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Zevra Therapeutics Inc   (NASDAQ: ZVRA)
 

ZVRA's Revenue Growth by Quarter and Year

Zevra Therapeutics Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/ZVRA/growth
https://api.csimarket.com/api/v1/companies/ZVRA/fundamentals
https://api.csimarket.com/api/v1/companies/ZVRA/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery
Connect Your AI Assistant
How to Connect Your AI Assistant to CSIMarket MCP MCP Server
Access this full dataset via API
Free sample Full docs All endpoints
ZVRA Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 37.76
2nd Quarter June 39.66
1st Quarter March 29.00
FY 106.42

ZVRAs Annual Revenue
Zevra Therapeutics Inc 's Revenue in the fiscal year 2025 $ 106.47 millions
Zevra Therapeutics Inc 's Revenue in the fiscal year 2024 $ 23.61 millions
Zevra Therapeutics Inc 's Revenue in the fiscal year 2023 $ 27.46 millions
Zevra Therapeutics Inc 's Revenue in the fiscal year 2022 $ 10.46 millions
Zevra Therapeutics Inc 's Revenue in the fiscal year 2021 $ 28.65 millions




ZVRA Revenue third quarter 2026 Y/Y Growth Comment
Zevra Therapeutics Inc reported Revenue rise of 44.88% year on year in the third quarter 2026, to $ 37.76 millions, this is lower than Zevra Therapeutics Inc 's recent average Revenue rise of 79.55%.

Looking into third quarter 2026 results within Major Pharmaceutical Preparations industry 46 other companies have achieved higher Revenue growth. While Zevra Therapeutics Inc ' s Revenue jump of 44.88% ranks overall at the positon no. 325 in the third quarter 2026.


ZVRA Revenue ( Y/Y Growth %) 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 44.88 %
2nd Quarter June 53.25 %
1st Quarter March 42.16 %
FY   -

Financial Statements
Zevra Therapeutics Inc 's third quarter 2026 Revenue $ 37.76 millions ZVRA's Income Statement
Zevra Therapeutics Inc 's third quarter 2025 Revenue $ 26.06 millions Quarterly ZVRA's Income Statement


ZVRA Revenue (Quarter on Quarter Growth %)

 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -4.8 %
2nd Quarter June 36.76 %
1st Quarter March -15.03 %
FY (Year on Year)   -


Back to ZVRA Growth rate Comparisons >> Back to ZVRA Growth rate Comparisons >>


Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #47
Healthcare Sector #87
Overall #325

Revenue Y/Y Growth Statistics
High Average Low
350.91 % 79.55 % -65.44 %
(Dec 31 2025)   (Jun 30 2022)
Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #47
Healthcare Sector #87
Overall #325
Revenue Y/Y Growth Statistics
High Average Low
350.91 % 79.55 % -65.44 %
(Dec 31 2025)   (Jun 30 2022)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Zevra Therapeutics Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
412.13 % 52.43 % -88 %
(Mar 31 2021)  


ZVRA's III. Quarter Q/Q Revenue Comment
In the III. Quarter 2026 Zevra Therapeutics Inc disclosed fall in Revenue from the second quarter by -4.8% to $ 37.76 millions, from $ 39.66 millions achived in the previous reporting period.

Although periodic circumstance commonly energize III. Quarter 2026 Revenue, this plainly could not be substantial to rescue Major Pharmaceutical Preparations's company achievement, Most analysts pointed out.

Within Major Pharmaceutical Preparations industry 36 other companies have achieved higher Revenue quarter on quarter growth. While Zevra Therapeutics Inc 's Revenue growth quarter on quarter, overall rank is 308.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #37
Healthcare Sector #75
Overall #308
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #37
Healthcare Sector #75
Overall #308
Revenue Q/Q Growth Statistics
High Average Low
412.13 % 52.43 % -88 %
(Mar 31 2021)  


ZVRA's III. Quarter Q/Q Revenue Comment
In the III. Quarter 2026 Zevra Therapeutics Inc disclosed fall in Revenue from the second quarter by -4.8% to $ 37.76 millions, from $ 39.66 millions achived in the previous reporting period.

Although periodic circumstance commonly energize III. Quarter 2026 Revenue, this plainly could not be substantial to rescue Major Pharmaceutical Preparations's company achievement, Most analysts pointed out.

Within Major Pharmaceutical Preparations industry 36 other companies have achieved higher Revenue quarter on quarter growth. While Zevra Therapeutics Inc 's Revenue growth quarter on quarter, overall rank is 308.


Zevra Therapeutics Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Sep 30 2026)		 12 Months Ending (Jun 30 2026) 12 Months Ending (Mar 31 2026) 12 Months Ending (Dec 31 2025) 12 Months Ending (Sep 30 2025)
Cumulative Revenue 12 Months Ending $ 140.55
Y / Y Revenue Growth (TTM) 66.55 %
Year on Year Revenue Growth Overall Ranking # 106
Seqeuential Revenue Change (TTM) 9.07 %
Seq. Revenue Growth (TTM) Overall Ranking # 325


Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Sep 30 2026 period, Zevra Therapeutics Inc 's cumulative twelve months Revenue were $ 141 millions, company would post below average annual Revenue growth of 9.07% year on year, if the fiscal year would end at Sep 30 2026.
A slow-down in the Zevra Therapeutics Inc 's Revenue growth from the 39.66% growth in Jun 30 2026.

Within the Healthcare sector 32 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 106, from total ranking in previous quarter at 192.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 47
Healthcare Sector # 33
Overall # 106

Revenue TTM Y/Y Growth Statistics
High Average Low
350.91 %
 79.55 %
-65.44 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 47
Sector # 87
S&P 500 # 325
Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Sep 30 2026 period, Zevra Therapeutics Inc 's cumulative twelve months Revenue were $ 141 millions, company would post below average annual Revenue growth of -65.44% year on year, if the fiscal year would end at Sep 30 2026.
A slow-down in the Zevra Therapeutics Inc 's Revenue growth from the 39.66% growth in Jun 30 2026.

Within the Healthcare sector 32 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 106, from total ranking in previous quarter at 192.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 47
Healthcare Sector # 33
Overall # 106

Revenue TTM Y/Y Growth Statistics
High Average Low
350.91 %
79.55 %
-65.44 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 47
Sector # 87
S&P 500 # 325




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
ZVRA's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue fall for the quarter ending Sep 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2026
Omniab Inc 78.34%$ 78.339 millions
Aclarion Inc 78.09%$ 78.086 millions
Personalis Inc 76.59%$ 76.585 millions
Delcath Systems Inc 76.05%$ 76.047 millions
Mobia Medical Inc 73.28%$ 73.280 millions
Wave Life Sciences Ltd 72.95%$ 72.950 millions
Igc Pharma Inc 71.73%$ 71.728 millions
Phathom Pharmaceuticals Inc 71.14%$ 71.142 millions
Ptc Therapeutics inc 69.57%$ 69.571 millions
Seres Therapeutics Inc 68.95%$ 68.946 millions
Alamar Biosciences Inc 68.46%$ 68.458 millions
Carlsmed Inc 66.74%$ 66.736 millions
Corcept Therapeutics Inc63.97%$ 63.974 millions
Tarsus Pharmaceuticals Inc 63.92%$ 63.921 millions
Tg Therapeutics Inc 60.74%$ 60.743 millions
Therapeuticsmd Inc 60.59%$ 60.587 millions
Heartflow Inc 60.42%$ 60.425 millions
Glaukos Corp59.02%$ 59.021 millions
X4 Pharmaceuticals Inc58.64%$ 58.640 millions
Kiniksa Pharmaceuticals International Plc58.12%$ 58.121 millions
Envoy Medical Inc 57.14%$ 57.143 millions
Humacyte Inc 55.21%$ 55.208 millions
Butterfly Network Inc 53.45%$ 53.453 millions
Avita Medical Inc 53.05%$ 53.054 millions
Immunitybio inc 52.34%$ 52.338 millions
Axsome Therapeutics Inc 51.87%$ 51.873 millions
Yunhong Green Cti Ltd 51.28%$ 51.282 millions
Innovative Eyewear Inc 51.12%$ 51.123 millions
Strata Critical Medical Inc 50.27%$ 50.272 millions
Madrigal Pharmaceuticals Inc 50.13%$ 50.127 millions


About Zevra Therapeutics Inc Revenue Growth Rates (ZVRA), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Zevra Therapeutics Inc (CIK 1434647).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001434647-26-000087
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Zevra Therapeutics Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.